These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51 related articles for article (PubMed ID: 8699332)
1. A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in mice. Srinivas NR; Weiner RS; Shyu WC; Calore JD; Tritschler D; Tay LK; Lee JS; Greene DS; Barbhaiya RH J Pharm Sci; 1996 Mar; 85(3):296-8. PubMed ID: 8699332 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of CTLA4lg (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses. Srinivas NR; Weiner RS; Warner G; Shyu WC; Davidson T; Fadrowski CG; Tay LK; Lee JS; Greene DS; Barbhaiya RH J Pharm Sci; 1996 Jan; 85(1):1-4. PubMed ID: 8926572 [TBL] [Abstract][Full Text] [Related]
3. Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats. Srinivas NR; Shyu WC; Weiner RS; Warner G; Comereski C; Tay LK; Greene DS; Barbhaiya RH Pharm Res; 1997 Jul; 14(7):911-6. PubMed ID: 9244149 [TBL] [Abstract][Full Text] [Related]
4. A sensitive enzyme immunoassay for the quantitation of human CTLA4Ig fusion protein in mouse serum: pharmacokinetic application to optimizing cell line selection. Weiner RS; Srinivas NR; Calore JD; Fadrowski CG; Shyu WC; Tay LK J Pharm Biomed Anal; 1997 Feb; 15(5):571-9. PubMed ID: 9127268 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following intravenous and subcutaneous administration to mice. Srinivas NR; Shyu WC; Weiner RS; Tay LK; Greene DS; Barbhaiya RH J Pharm Sci; 1995 Dec; 84(12):1488-9. PubMed ID: 8748333 [No Abstract] [Full Text] [Related]
6. CTLA4Ig inhibits airway eosinophilia and hyperresponsiveness by regulating the development of Th1/Th2 subsets in a murine model of asthma. Padrid PA; Mathur M; Li X; Herrmann K; Qin Y; Cattamanchi A; Weinstock J; Elliott D; Sperling AI; Bluestone JA Am J Respir Cell Mol Biol; 1998 Apr; 18(4):453-62. PubMed ID: 9533932 [TBL] [Abstract][Full Text] [Related]
7. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy. Siegall CB; Haggerty HG; Warner GL; Chace D; Mixan B; Linsley PS; Davidson T J Immunol; 1997 Nov; 159(10):5168-73. PubMed ID: 9366448 [TBL] [Abstract][Full Text] [Related]
8. Prolongation of rat to mouse skin and heart xenograft survival by combined CTLA4Ig and anti-CD4/CD8 antibody. Tu Y; Rehman A; Flye MW Transplant Proc; 1996 Aug; 28(4):2061-2. PubMed ID: 8769156 [No Abstract] [Full Text] [Related]
10. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. Mihara M; Tan I; Chuzhin Y; Reddy B; Budhai L; Holzer A; Gu Y; Davidson A J Clin Invest; 2000 Jul; 106(1):91-101. PubMed ID: 10880052 [TBL] [Abstract][Full Text] [Related]
11. Preventing allograft rejection with CTLA4IG: effect of donor-specific transfusion route or timing. Bolling SF; Lin H; Wei RQ; Turka LA J Heart Lung Transplant; 1996 Sep; 15(9):928-35. PubMed ID: 8889989 [TBL] [Abstract][Full Text] [Related]
12. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. Via CS; Rus V; Nguyen P; Linsley P; Gause WC J Immunol; 1996 Nov; 157(9):4258-67. PubMed ID: 8892665 [TBL] [Abstract][Full Text] [Related]
13. Prolongation of skin allograft survival in mice treated with CTLA-4 Ig in combination with rapamycin or cyclosporine. Hale DA; Gottschalk R; Wood ML; Maki T; Monaco AP Transplant Proc; 1996 Dec; 28(6):3270-1. PubMed ID: 8962270 [No Abstract] [Full Text] [Related]
14. The effect of combination cyclosporine and CTLA4-Ig therapy on cardiac allograft survival. Bolling SF; Lin H; Wei RQ; Linsley P; Turka LA J Surg Res; 1994 Jul; 57(1):60-4. PubMed ID: 8041150 [TBL] [Abstract][Full Text] [Related]
15. Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig. Saha B; Jaklic B; Harlan DM; Gray GS; June CH; Abe R J Immunol; 1996 Nov; 157(9):3869-75. PubMed ID: 8892617 [TBL] [Abstract][Full Text] [Related]
16. [Preoperative inoculation of CTLA4Ig combined with allogeneic dendritic cells prolongs rat renal allograft survival in a donor-specific fashion]. Harada H Hokkaido Igaku Zasshi; 1999 May; 74(3):189-98. PubMed ID: 10422563 [TBL] [Abstract][Full Text] [Related]